Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label epoprostenol (ACT-385781A) in pulmonary arterial hypertension
jRCT1080221971Phase 3
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epoprostenol in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy and Heritable Pulmonary Arterial Hypertension (HPAH), sponsored by Actelion Pharmaceuticals Ltd.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on jRCT1080221971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221971.